Information Journal Paper
APA:
Copy. (2017). Estimated burden of cardiovascular disease and value-based price range for evolocumab in a high-risk, secondary-prevention population in the US payer context. JOURNAL OF MEDICAL ECONOMICS, 20(6), 555-564. SID. https://sid.ir/paper/690027/en
Vancouver:
Copy. Estimated burden of cardiovascular disease and value-based price range for evolocumab in a high-risk, secondary-prevention population in the US payer context. JOURNAL OF MEDICAL ECONOMICS[Internet]. 2017;20(6):555-564. Available from: https://sid.ir/paper/690027/en
IEEE:
Copy, “Estimated burden of cardiovascular disease and value-based price range for evolocumab in a high-risk, secondary-prevention population in the US payer context,” JOURNAL OF MEDICAL ECONOMICS, vol. 20, no. 6, pp. 555–564, 2017, [Online]. Available: https://sid.ir/paper/690027/en